Literature DB >> 17556867

Association of insulin resistance and nocturnal fall of blood pressure in GH-deficient adults during GH replacement.

R Resende de Lima Oliveira Brasil1, D Vieira Soares, L Diniz Carneiro Spina, P Marise Lobo, E Maria Carvalho da Silva, V Aleta Mansur, M F Miguens Castelar Pinheiro, F L Conceição, M Vaisman.   

Abstract

The GH deficiency syndrome in adults is characterized by changes in body composition, metabolic, cardiovascular and psychological profile. Such alterations fit the metabolic syndrome. Changes of blood pressure (BP) levels related to the presence of insulin resistance (IR) may be present in the GH-deficient adult prior to or after therapy with recombinant GH (hGH). The purpose of the study was to assess the relationship between BP and IR in GH-deficient adults after 24 months of replacement with hGH. Thirteen GH-deficient adults were studied [7 men and 6 women, with an average age of 38.6+/-14.14 yr body mass index (BMI) 25.83+/-2.26 kg/m2]. The BP was assessed by means of ambulatory monitoring of BP (AMBP), prior to the treatment and 12 and 24 months after replacement with hGH. Glucose metabolism was assessed by the homeostatic model assessment (HOMA), during the same periods. The average dosage of hGH utilized was 0.67+/-0.15 mg/day. In the analysis of BP levels, we observed a decrease of the diurnal systolic BP (SB P) (p=0.043) and a reduction of the diurnal systolic (p=0.002) and diastolic pressure loads (p=0.038). During the night there were no changes in BP levels. We observed an increase in the percentage of patients with a non-physiological nocturnal fall (non dippers) after replacement with hGH (61.53%). The mean HOMA, insulin and glucose in the fasting state did not present any statistically significant changes. Although the patients within the nondipper group had higher HOMA and insulin levels throughout the study, there were no changes in any of these parameters after GH replacement. All patients with HOMA >2.5 were within the non-dipper group, whereas all dippers had HOMA <2.5. In conclusion, 24 months of therapy with hGH do not seem to have affected glucose homeostasis, and since there is no relationship with the increase of the percentage of non-physiological nocturnal fall, we will need a longer observation time to discover the effects of this finding.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17556867     DOI: 10.1007/BF03346297

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  34 in total

Review 1.  Growth hormone therapy in adults.

Authors:  F L Conceição; A Bojensen; J O Jørgensen; J S Christiansen
Journal:  Front Neuroendocrinol       Date:  2001-07       Impact factor: 8.606

Review 2.  The growth hormone deficiency syndrome in adults.

Authors:  R C Cuneo; F Salomon; G A McGauley; P H Sönksen
Journal:  Clin Endocrinol (Oxf)       Date:  1992-11       Impact factor: 3.478

3.  Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives.

Authors:  Guido Grassi; Raffaella Dell'Oro; Annalisa Facchini; Fosca Quarti Trevano; Giovanni Battista Bolla; Giuseppe Mancia
Journal:  J Hypertens       Date:  2004-12       Impact factor: 4.844

4.  The clinical significance of diurnal blood pressure variations. Dippers and nondippers.

Authors:  T G Pickering
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

Review 5.  Malfunction of vascular control in lifestyle-related diseases: mechanisms underlying endothelial dysfunction in the insulin-resistant state.

Authors:  Kazuya Shinozaki; Kazuhide Ayajiki; Atsunori Kashiwagi; Masahiro Masada; Tomio Okamura
Journal:  J Pharmacol Sci       Date:  2004-12-15       Impact factor: 3.337

Review 6.  Clinical aspects of growth hormone deficiency in adults.

Authors:  H de Boer; G J Blok; E A Van der Veen
Journal:  Endocr Rev       Date:  1995-02       Impact factor: 19.871

7.  Effects of 7 years of growth hormone replacement therapy in hypopituitary adults.

Authors:  A Chrisoulidou; S A Beshyah; O Rutherford; T J Spinks; J Mayet; P Kyd; V Anyaoku; A Haida; B Ariff; M Murphy; E Thomas; S Robinson; R Foale; D G Johnston
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

8.  Ambulatory monitoring of blood pressure in growth hormone-deficient adults.

Authors:  Flávia L Conceição; Vera Aleta de Rooij Mansur; Rosane R L O Brasil; Mario Vaisman
Journal:  Blood Press Monit       Date:  2002-04       Impact factor: 1.444

9.  Insulin resistance and the effect of insulin on blood pressure in essential hypertension.

Authors:  T Heise; K Magnusson; L Heinemann; P T Sawicki
Journal:  Hypertension       Date:  1998-08       Impact factor: 10.190

Review 10.  Insulin and insulin resistance: impact on blood pressure and cardiovascular disease.

Authors:  James R Sowers; Edward D Frohlich
Journal:  Med Clin North Am       Date:  2004-01       Impact factor: 5.456

View more
  1 in total

1.  Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency.

Authors:  Maria Claudia Peixoto Cenci; Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Vera Aleta Mansur; Jaime Gold; Eduardo Michmacher; Mario Vaisman; Flávia Lúcia Conceição
Journal:  Pituitary       Date:  2009-04-24       Impact factor: 4.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.